Introduction | KNK437 (218924-25-5) Inhibits Constitutive and inducible HSP70 expression in non-stressed and heat-stressed cancer cells. Blocks geldanamycin-induced HSP70 induction and inhibition of TGF signaling. Inhibition of leukocyte integrin α-7-mediated T cell adhesion to Mucosal addressin cell adhesion molecule 1 (MAdCAM-1) suggests that HSP70 is critical for 7 integrin signaling. Inhibits morphine analgesia tolerance in a rodent model (100 mg/Kg). |
biological activity | KNK437 is a pan-HSP inhibitor that inhibits inducible HSPs, including HSP105,HSP72, and synthesis of hsp40. |
Target | TargetValue HSP105 () HSP72 () HSP40 () |
Target | Value |
in vitro study | in COLO 320DM (human colon cancer) cells, KNK437 dose-dependently inhibited the acquisition of Thermotolerance and the activity of individual HSPs, including Hsp105, HSP70 and hsp40. KNK437 and quercetin dose-dependently inhibited Thermotolerance in PC-3 cells. KNK437 reduced heat-induced accumulation of HSP70 mRNA and protein in PC-3 and LNCaP cells. |
in vivo studies | KNK437(200 mg/kg, I. P.), and does not increase the temperature sensitivity of non resistant tumors. The same dose of KNK437 synergistically increased the anti-tumor efficacy of the graded heat treatment. |